| Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation |
| 論文作者 |
Wang, K; Xiang, YJ; Yu, HM; Cheng, YQ; Feng, JK; Liu, ZH; Shan, YF; Zheng, YT; Ni, QZ; Cheng, SQ |
| 期刊/會議名稱 |
BMC CANCER |
| 論文年度 |
2023 |
| 論文類別 |
Article |
| 摘要 |
Background The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research has been conducted on the overall survival (OS) of patients with varying tumor responses and treatment duration. Methods This retrospective study analyzed HCC patients who received sintilimab between January 2019 and December 2020 at four centers in China. The evaluation of tumor progression was based on Response Evaluation Criteria in Solid Tumors version 1.1. The study investigated the correlation between tumor response and OS, and the impact of drug use on OS following progressive disease (PD). Results Out of 441 treated patients, 159 patients satisfied the inclusion criteria. Among them, 77 patients with disease control exhibited a significantly longer OS compared to the 82 patients with PD (median OS 26.0 vs. 11.3 months, P < 0.001). Additionally, the OS of patients with objective response (OR) was better than that of patients with stable disease (P = 0.002). Among the 47 patients with PD who continued taking sintilimab, the OS was better than the 35 patients who discontinued treatment (median OS 11.4 vs. 6.9 months, P = 0.042). Conclusions In conclusion, the tumor response in HCC patients who received sintilimab affects OS, and patients with PD may benefit from continued use of sintilimab. |
| 期 |
1 |
| 卷 |
23 |
| 影響因子 |
3.8 |
官方微信
